How big is the Glaucoma Treatment Market?

The Glaucoma Treatment Market size is expected to reach USD 6.40 billion in 2024 and grow at a CAGR of 4.60% to reach USD 8.02 billion by 2029. Read More

What is the current Glaucoma Treatment Market size?

In 2024, the Glaucoma Treatment Market size is expected to reach USD 6.40 billion. Read More

Who are the key players in Glaucoma Treatment Market?

AERIE PHARMACEUTICALS, INC., Akorn, Incorporated, Allergan Plc, Bausch & Lomb Incorporated and Novartis AG are the major companies operating in the Glaucoma Treatment Market. Read More

Which is the fastest growing region in Glaucoma Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Glaucoma Treatment Market?

In 2024, the North America accounts for the largest market share in Glaucoma Treatment Market. Read More

What years does this Glaucoma Treatment Market cover, and what was the market size in 2023?

In 2023, the Glaucoma Treatment Market size was estimated at USD 6.11 billion. The report covers the Glaucoma Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Glaucoma Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Glaucoma Treatment Market Trends

Statistics for the 2023 & 2024 Glaucoma Treatment market trends, created by Mordor Intelligence™ Industry Reports. Glaucoma Treatment trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Glaucoma Treatment Industry

Prostaglandin Analogs is the Segment by Drug Class that is Expected to Witness Fastest Growth Over the Forecast Period

Prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. They have few systemic side effects but are associated with changes to the eye itself, including change in iris color and growth of eyelashes. Depending on the individual, one brand of this type of medication may be more effective and produce fewer side effects.

Prostaglandin analogs are taken as eye drops. They are effective at reducing intraocular pressure in people who have open-angle glaucoma. Latanoprost and some formulations of bimatoprost and travoprost are now available in generic form. Tafluprost is a preservative-free prostaglandin analog.

The demand for these drugs is expected to rise as the incidence of glaucoma has increased over the past few years due to the aging population. Moreover, the incidence of the disease is expected to increase in the future as the population aged 60 years and over are expected to increase from 12.7% in 2017 to 21.3% by 2050, as per a 2017 report by the United Nations. Increasing geriatric population is expected to increase the prevalence of glaucoma, as the disaese is more prevalent in the elderly. Hence the demand for Prostaglandin Analogs is also expected to increase, which will boost the market growth.

Glaucoma Treatment Market: Percentage of Population aged 60 years and Above, Global, 2017

Understand The Key Trends Shaping This Market

Download PDF

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest glaucoma treatment market owing to the rising cases of glaucoma and the presence of better healthcare infrastructure. As per the data published by the BrightFocus Foundation more than 3 million Americans are living with glaucoma and open-angle glaucoma is the most common form of glaucoma.

Furthermore, glaucoma costs to the United States economy around USD 2.86 billion every year in direct costs and productivity losses. Also, there are various organizations in the United States creating awareness regarding glaucoma which is expected to propel the overall growth of the market.